ProNAi to Present at the 33rd Annual J.P. Morgan Healthcare Conference

VANCOUVER and PLYMOUTH, MI, Jan. 12, 2015 /CNW/ - ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi® platform, today announced that it has been invited to present at the 33rd Annual J.P. Morgan Healthcare Conference being held this week in San Francisco. Dr. Nick Glover, President and CEO of ProNAi, will provide an update on the Company's development program for its lead DNAi therapeutic, PNT2258, on January 15, 2015 at 11:30 a.m. PST in room Elizabethan D.

About ProNAi Therapeutics

ProNAi Therapeutics is a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi platform for patients with cancer and hematological diseases. ProNAi's lead DNAi drug PNT2258 is specifically designed to treat cancers that overexpress BCL2. To date, PNT2258 has been studied in a Phase I and a pilot Phase II clinical trial, with compelling efficacy and safety results reported. ProNAi recently enrolled the first patient in the "Wolverine" Phase II study evaluating PNT2258 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). For more information, please visit

SOURCE ProNAi Therapeutics Inc.

For further information: James Smith, VP Corporate Affairs, ProNAi Therapeutics Inc., 734.233.3966,